Literature DB >> 7361721

Factor X assays using chromogenic substrate S-2222.

A Girolami, L Saggin, G Boeri.   

Abstract

Factor X was assayed using chromogenic substrate S-2222 for four patients with severe factor X deficiency and for nine patients with homozygous or heterozygous factor X Friuli disorder. Factor X Friuli disorder is characterized by the presence of an abnormal factor X that is normally activated by Russell's viper venom, but is not activated by tissue thromboplastins. The levels of factor X found in factor X deficiency varied between 2 and 10% of normal and therefore were higher than those found in the same plasmas using "clotting" methods (1% or less than 1% of normal). The levels of factor X found in homozygous factor X Friuli patients varied between 4 and 11% of normal, and therefore were practically identical to those found by means of clotting methods that employed tissue thromboplastins (7-9% of normal). These values were definitely lower than those obtained using a Russell's viper venom and cephalin mixture as thromboplastin (82-92%). A similar pattern was observed for patients heterozygous for the abnormality. These findings indicate that "amidolytic" methods are not necessarily identical to clotting methods. Furthermore, they indicate that substrate S-2222 is not specific for factor X.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7361721     DOI: 10.1093/ajcp/73.3.400

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  3 in total

1.  Factor X and pancreatic islet A cell.

Authors:  C Betterle; A Trevisan; A Girolami
Journal:  Blut       Date:  1982-12

2.  A family with heterozygous factor X Friuli defect outside Friuli.

Authors:  A Girolami; M Lazzarin; M Procidano; G Luzzatto
Journal:  Blut       Date:  1983-03

3.  A new family with classical factor X deficiency as demonstrated by electroimmunoassay.

Authors:  A Girolami; G Luzzatto; N Scattolo; F A Zanolli
Journal:  Blut       Date:  1983-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.